GB2591681A — Methotrexate pharmaceutical composition
Assigned to FTF Pharma Pvt Ltd · Expires 2021-08-04 · 5y expired
What this patent protects
Though oral liquid formulations of Methotrexate are advantageous as they can suitably be administered to the patients having swallowing difficulties such as pediatric patients, geriatric patients, stroke patients or patients who are unable to take solid oral therapy, they are not…
USPTO Abstract
Though oral liquid formulations of Methotrexate are advantageous as they can suitably be administered to the patients having swallowing difficulties such as pediatric patients, geriatric patients, stroke patients or patients who are unable to take solid oral therapy, they are not much explored in the prior art. Further, liquid formulations of Methotrexate known in the prior art have not been explored at higher pH and in the absence of additional solubilizing agents. An aim of the present invention is therefore to provide chemically and physically stable liquid pharmaceutical compositions of Methotrexate at higher pH and in the absence of solubilizing agents.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.